Nanjing Hicin Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
April 21, 2022 at 09:40 am
Share
Nanjing Hicin Pharmaceutical Co., Ltd. reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported sales was CNY 150.61 million compared to CNY 162.2 million a year ago. Revenue was CNY 150.61 million compared to CNY 162.2 million a year ago. Net income was CNY 12.62 million compared to CNY 13.51 million a year ago. Basic earnings per share from continuing operations was CNY 0.1052 compared to CNY 0.1126 a year ago. Diluted earnings per share from continuing operations was CNY 0.1052 compared to CNY 0.1126 a year ago.
Nanjing Hicin Pharmaceutical Co Ltd is a pharmaceutical company engaged in research, development and production of chemical preparations, active pharmaceutical ingredients and intermediates. The Company's primary products are torsemide for injection, tigecycline for injection, cefoxitin sodium for injection, cefotiam for injection and omeprazole sodium for injection. The torsemide for injection is a loop diuretic. The tigecycline for injection is an intravenous administrated glycyrrhizin antibiotic for the treatment of complex skin and skin structure infections or complex intra-abdominal infections. The cefoxitin sodium for injection is a cephalosporin antibiotic used for the treatment of respiratory, urinary and gastrointestinal infections. Its products cover a range of therapeutic areas, including diuresis, cardiovascular, anti-infection, digestive system, immune regulation, hypoglycemic and orthopedics.